Protagenic Therapeutics, Inc.\new (PTIX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
9/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePTIX / S&P -42.18% / 15.20% |
LosePTIX / S&P PTIX unavailable / 15.00% |
LosePTIX / S&P -212.63% / 50.40% |
| 2026-Q10/3 |
LosePTIX / S&P -47.85% / -4.33% |
LosePTIX / S&P PTIX unavailable / 11.30% |
LosePTIX / S&P -243.30% / 27.70% |
| 2025-Q40/3 |
LosePTIX / S&P -62.10% / 2.65% |
LosePTIX / S&P PTIX unavailable / 9.00% |
LosePTIX / S&P -82.87% / 13.40% |
| 2025-Q30/3 |
LosePTIX / S&P -6.03% / 8.12% |
LosePTIX / S&P PTIX unavailable / 4.61% |
LosePTIX / S&P -62.80% / 13.45% |
| 2025-Q21/3 |
WinPTIX / S&P 33.70% / 10.94% |
LosePTIX / S&P PTIX unavailable / 4.83% |
LosePTIX / S&P -69.54% / 10.63% |
| 2025-Q10/3 |
LosePTIX / S&P -60.20% / -4.27% |
LosePTIX / S&P PTIX unavailable / 4.98% |
LosePTIX / S&P -84.89% / 10.57% |
| 2024-Q41/3 |
LosePTIX / S&P -21.85% / 2.41% |
LosePTIX / S&P PTIX unavailable / 5.25% |
WinPTIX / S&P 427.83% / 6.15% |
| 2024-Q31/3 |
LosePTIX / S&P -30.72% / 5.89% |
LosePTIX / S&P PTIX unavailable / 5.89% |
WinPTIX / S&P 591.21% / 6.11% |
| 2024-Q21/3 |
LosePTIX / S&P -48.29% / 4.28% |
LosePTIX / S&P PTIX unavailable / 5.38% |
WinPTIX / S&P 712.50% / 5.12% |
| 2024-Q12/3 |
WinPTIX / S&P 76.77% / 10.56% |
LosePTIX / S&P PTIX unavailable / 5.71% |
WinPTIX / S&P 858.21% / 5.59% |
| 2023-Q40/3 |
LosePTIX / S&P -46.20% / 11.69% |
LosePTIX / S&P PTIX unavailable / 6.81% |
LosePTIX / S&P PTIX unavailable / 7.78% |
| 2023-Q30/3 |
LosePTIX / S&P -9.36% / -3.27% |
LosePTIX / S&P PTIX unavailable / 7.52% |
LosePTIX / S&P PTIX unavailable / -5.03% |
| 2023-Q21/3 |
WinPTIX / S&P 17.34% / 8.74% |
LosePTIX / S&P PTIX unavailable / 9.50% |
LosePTIX / S&P PTIX unavailable / -8.57% |
| 2023-Q11/3 |
WinPTIX / S&P 8.12% / 7.50% |
LosePTIX / S&P PTIX unavailable / 10.77% |
LosePTIX / S&P PTIX unavailable / -15.69% |
| 2022-Q40/3 |
LosePTIX / S&P -29.95% / 7.56% |
LosePTIX / S&P PTIX unavailable / 11.88% |
LosePTIX / S&P PTIX unavailable / -17.99% |
| 2022-Q30/3 |
LosePTIX / S&P -21.13% / -4.88% |
LosePTIX / S&P PTIX unavailable / 13.47% |
LosePTIX / S&P PTIX unavailable / -1.41% |
| 2022-Q21/3 |
WinPTIX / S&P -11.17% / -16.10% |
LosePTIX / S&P PTIX unavailable / 13.71% |
LosePTIX / S&P PTIX unavailable / 11.04% |
| 2022-Q10/3 |
LosePTIX / S&P -41.16% / -4.60% |
LosePTIX / S&P PTIX unavailable / 15.97% |
LosePTIX / S&P PTIX unavailable / 42.23% |
| 2021-Q40/3 |
LosePTIX / S&P -25.94% / 11.03% |
LosePTIX / S&P PTIX unavailable / 15.00% |
LosePTIX / S&P PTIX unavailable / 96.40% |
| 2021-Q30/3 |
LosePTIX / S&P -35.07% / 0.58% |
LosePTIX / S&P PTIX unavailable / 10.77% |
LosePTIX / S&P PTIX unavailable / 69.42% |
| 2021-Q20/3 |
LosePTIX / S&P PTIX unavailable / 8.55% |
LosePTIX / S&P PTIX unavailable / 6.58% |
LosePTIX / S&P PTIX unavailable / 51.81% |
| 2021-Q10/3 |
LosePTIX / S&P PTIX unavailable / 6.17% |
LosePTIX / S&P PTIX unavailable / -1.06% |
LosePTIX / S&P PTIX unavailable / 7.39% |
| 2020-Q40/3 |
LosePTIX / S&P PTIX unavailable / 12.15% |
LosePTIX / S&P PTIX unavailable / -3.72% |
LosePTIX / S&P PTIX unavailable / -33.42% |
| 2020-Q30/3 |
LosePTIX / S&P PTIX unavailable / 8.93% |
LosePTIX / S&P PTIX unavailable / -2.04% |
LosePTIX / S&P PTIX unavailable / -27.10% |
| 2020-Q20/3 |
LosePTIX / S&P PTIX unavailable / 20.54% |
LosePTIX / S&P PTIX unavailable / -0.46% |
LosePTIX / S&P PTIX unavailable / -27.11% |
| 2020-Q10/3 |
LosePTIX / S&P PTIX unavailable / -19.60% |
LosePTIX / S&P PTIX unavailable / 3.47% |
LosePTIX / S&P PTIX unavailable / -14.75% |
| 2019-Q40/3 |
LosePTIX / S&P PTIX unavailable / 9.07% |
LosePTIX / S&P PTIX unavailable / 5.36% |
LosePTIX / S&P PTIX unavailable / 2.99% |
| 2019-Q30/3 |
LosePTIX / S&P PTIX unavailable / 1.70% |
LosePTIX / S&P PTIX unavailable / 5.02% |
LosePTIX / S&P PTIX unavailable / 0.21% |
| 2019-Q20/3 |
LosePTIX / S&P PTIX unavailable / 4.30% |
LosePTIX / S&P PTIX unavailable / 6.64% |
LosePTIX / S&P PTIX unavailable / 8.65% |
| 2019-Q10/3 |
LosePTIX / S&P PTIX unavailable / 13.65% |
LosePTIX / S&P PTIX unavailable / 8.12% |
LosePTIX / S&P PTIX unavailable / 14.29% |
| 2018-Q40/3 |
LosePTIX / S&P PTIX unavailable / -13.52% |
LosePTIX / S&P PTIX unavailable / 9.05% |
LosePTIX / S&P PTIX unavailable / 18.23% |
| 2018-Q30/3 |
LosePTIX / S&P PTIX unavailable / 7.71% |
LosePTIX / S&P PTIX unavailable / 10.21% |
LosePTIX / S&P PTIX unavailable / 19.06% |
| 2018-Q20/3 |
LosePTIX / S&P PTIX unavailable / 3.43% |
LosePTIX / S&P PTIX unavailable / 9.03% |
LosePTIX / S&P PTIX unavailable / 14.46% |
| 2018-Q10/3 |
LosePTIX / S&P PTIX unavailable / -0.76% |
LosePTIX / S&P PTIX unavailable / 7.68% |
LosePTIX / S&P PTIX unavailable / 12.46% |
| 2017-Q40/3 |
LosePTIX / S&P PTIX unavailable / 6.64% |
LosePTIX / S&P PTIX unavailable / 7.03% |
LosePTIX / S&P PTIX unavailable / 13.82% |
| 2017-Q30/3 |
LosePTIX / S&P PTIX unavailable / 4.48% |
LosePTIX / S&P PTIX unavailable / 5.68% |
LosePTIX / S&P PTIX unavailable / 17.57% |
| 2017-Q20/3 |
LosePTIX / S&P PTIX unavailable / 3.09% |
LosePTIX / S&P PTIX unavailable / 4.83% |
LosePTIX / S&P PTIX unavailable / 17.74% |
| 2017-Q10/3 |
LosePTIX / S&P PTIX unavailable / 6.07% |
LosePTIX / S&P PTIX unavailable / 3.67% |
LosePTIX / S&P PTIX unavailable / 13.32% |
| 2016-Q40/3 |
LosePTIX / S&P PTIX unavailable / 3.82% |
LosePTIX / S&P PTIX unavailable / 2.09% |
LosePTIX / S&P PTIX unavailable / 7.05% |
| 2016-Q30/3 |
LosePTIX / S&P PTIX unavailable / 3.85% |
LosePTIX / S&P PTIX unavailable / 0.20% |
LosePTIX / S&P PTIX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PTIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -74.03% | 20.78% |
| Annualized return | -74.03% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PTIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.20% | 83.14% |
| Annualized return | -61.94% | 12.86% |
10Y · 2021-04-27 to 2026-08-27
| Metric | PTIX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.26% | 319.30% |
| Annualized return | -38.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |